EQT Is Paying £10.9 Billion for Intertek. Here Is What the Biggest UK PE Deal of 2026 Tells Accredited Investors.

Private Equity June 23, 2026

EQT Is Paying £10.9 Billion for Intertek. Here Is What the Biggest UK PE Deal of 2026 Tells Accredited Investors.

By Jeff Barnes, MBA

TL;DR

EQT agreed on June 18, 2026 to acquire Intertek Group at £61.08 per share, a 40% premium to the undisturbed share price. Total enterprise value: £10.9 billion. ADIA put in £1.0 billion for a 16% co-investment stake. Mubadala added £0.5 billion for 8%. EQT retains 76% via Isotope Bidco Limited. This is the UK's third-largest take-private on record. If you are an accredited investor watching private equity deployment, this deal is worth studying closely.

The deal that closed the debate about whether large-cap UK assets are cheap arrived on a Wednesday morning. On June 18, 2026, EQT announced a recommended final cash acquisition of Intertek Group plc at £60.00 per share in cash plus a 107.7 pence final dividend, totaling £61.08 per share. Equity value came to £9.5 billion. Add in net debt, and the enterprise value lands at £10.9 billion, or roughly $14.5 billion USD. This is the third-largest take-private in UK history, behind BAA in 2006 and Alliance Boots in 2007. I have covered private equity capital flows for years, and this transaction has layers that most coverage has missed.

The Contrarian Read: The Market Had Already Told You Intertek Was Mispriced

Most analysts are framing this as a bold EQT move. I think that misses the point. The real story is how badly the public market had already discounted Intertek before EQT showed up.

Consider the bid sequence. EQT's first approach on April 10 came in at £51.50 per share. Intertek's board rejected it. EQT came back at £54. Rejected. Then £58. Rejected again. The final accepted bid landed at £60 cash plus the dividend. That four-approach negotiation over roughly ten weeks ended at a 40% premium to the undisturbed mid-April price, and a 64% premium to where the stock was trading in early April before any rumor of the deal got out.

A 40% to 64% spread above recent trading levels is not just a buyout premium. It is a signal that the public market was pricing Intertek at a meaningful discount to intrinsic value for an extended period. Sterling weakness played a part. Investor skepticism about Intertek's organic "Assurance, Accreditation, and Acceleration" strategy, which management had been executing since 2023, also weighed on sentiment. When a sophisticated private buyer is willing to move from £51.50 to £60 across four rounds of rejection, that buyer has conviction in a valuation gap that the public market refused to close on its own.

You should think about what that means for other FTSE 100 industrial and services companies trading below replacement value. We have tracked the inbound PE interest in UK-listed companies throughout 2026, and Intertek is not an anomaly. It is a leading indicator.

The Numbers You Need to Know

Intertek is not a cyclical industrial. It is a testing, inspection, and certification business serving consumer goods, chemicals, energy, and business assurance clients across more than 100 countries. That matters for how you underwrite the deal economics.

In fiscal year 2025, Intertek posted a 34% adjusted operating margin. The company invested £600 million organically and through acquisitions between 2023 and 2025, completing seven deals during that window. Revenue is contract-based and recurring. Clients do not stop submitting products for certification because the economy slows. Regulatory bodies do not reduce testing requirements in a recession. That is exactly the kind of cash flow profile that justifies a £10.9 billion check.

According to Private Equity Insights analysis of the co-investment structure, ADIA committed £1.0 billion for a 16% post-close stake and Mubadala committed £0.5 billion for an 8% stake. EQT holds the remaining 76% through the acquisition vehicle Isotope Bidco Limited. That capital table is important. Sovereign wealth funds do not write nine-figure checks into buyouts for financial engineering purposes. They write those checks because they want long-duration exposure to high-quality cash flows, and they want the operational upside that a PE sponsor like EQT can unlock through portfolio company management.

The UK M&A backdrop amplifies all of this. ECM Source data shows UK M&A volume year-to-date in 2026 has already reached approximately £192 billion, an annualized pace that would more than double the £140 billion recorded across all of 2025. The Intertek deal is the flagship transaction in a record-setting year for UK corporate activity.

How the Mechanism Actually Works

Understanding why this deal gets done at this price requires looking at three intersecting forces.

First, currency. Sterling has remained weak relative to the dollar and the euro throughout 2025 and into 2026. EQT is a Swedish-headquartered firm with a euro-denominated flagship fund. When you buy a pound-denominated asset with euros, every percent of sterling weakness is a percent of discount baked into your basis cost. That discount is real and immediate. The exit multiple five years from now, if Intertek is re-listed or sold to a strategic buyer, will likely be priced in a stronger sterling environment. That FX tailwind is structural, not speculative.

Second, the bolt-on platform. EQT's stated rationale for the acquisition, articulated by Matthias Wittkowski, EQT's Global Head of Services, centers on Intertek as a platform for continued consolidation in the fragmented testing, inspection, and certification sector. Intertek already proved it can acquire and integrate at scale: seven acquisitions and £600 million deployed in two years, maintaining a 34% operating margin throughout. EQT's job is to accelerate that playbook. The TIC sector globally is populated by hundreds of regional operators that lack the capital and technology investment of Intertek. Buying them is the value creation thesis. The testing, inspection, and certification consolidation trade is one we have written about directly on this site, and it remains one of the more defensible roll-up strategies in services PE.

Third, activist pressure had already begun softening up the board. Palliser Capital and PrimeStone Capital, two activist shareholders, had been publicly pushing Intertek management to consider strategic alternatives. Matthew Peltz's Lost Coast Collective also held a position. When an activist campaign is already in motion and a credible buyer shows up at a 40% premium, the board's fiduciary calculus shifts quickly. That is exactly what happened here.

The advisory lineup reflects the deal's scale. Intertek retained Freshfields and Slaughter and May on the legal side, with Morgan Stanley, Barclays, and PJT Partners as financial advisors. EQT worked with Simpson Thacher, Deutsche Bank, JPMorgan, and Goldman Sachs. A six-bank advisory roster is not a sign that this deal was quietly negotiated. It was fully contested, and the final price reflects it.

If you want the regulatory filing detail, the official Rule 2.7 announcement filed by Intertek on June 18 under the UK Takeover Code is the primary document. It is dense but worth reading if you are evaluating the structure.

The Risks You Should Not Ignore

I am not here to sell you on this trade. There are real risks in this deal structure.

The £10.9 billion price implies an enterprise value multiple that is aggressive by historical TIC sector standards. EQT is counting on sustained margin expansion and a strong bolt-on pipeline to generate the returns its fund investors expect. If acquisition targets in the TIC space get more expensive, or if integration execution slips, the platform thesis gets harder to execute.

Regulatory scrutiny is a second factor. A deal this size, spanning over 100 countries, will face competition review in multiple jurisdictions. The UK's Competition and Markets Authority has become more active in recent years. That process adds time and cost, and in rare cases results in remedies that change deal economics.

The co-investment structure with ADIA and Mubadala is aligned at entry but could create governance friction over time. Sovereign wealth funds have long investment horizons. PE sponsors have fund lifecycle pressures that create exit timing expectations. When a £10.9 billion asset needs to be sold or re-listed, all three parties need to agree on process, price, and timing. That alignment is not guaranteed.

Finally, the currency tailwind I described above can reverse. If sterling strengthens significantly before EQT reaches its exit, euro-denominated returns get compressed. That is a real factor, not a theoretical one.

The Independent's coverage of the deal noted the broader concern among UK market observers that continued take-privates of this scale represent a long-term drain on the depth of the London Stock Exchange. Whether that risk materializes into sustained underperformance for UK public markets is a separate question from whether this individual deal works for EQT. Both can be true simultaneously.

What You Should Do With This Information

If you are an accredited investor with exposure to private equity funds, the Intertek deal is a case study in how the current environment rewards patient buyers who understand the gap between public market pricing and private market value.

Here is the actionable framework I would apply. Start by looking at your existing PE allocations. Are you in funds with the mandate and capital base to participate in deals of this scale? Most individual accredited investors are not in flagship EQT funds. But the co-investment model that brought ADIA and Mubadala into this deal is increasingly available through platforms that offer access to sovereign wealth co-investment vehicles and secondary interests. We have mapped the co-investment access options for accredited investors with minimum commitments below $1 million in a separate piece worth reviewing alongside this one.

Second, update your watchlist for similar situations. UK-listed industrials and services companies with recurring revenue, strong margins, and activist investor pressure are the profile EQT just validated at £10.9 billion. You will not be buying them at the public market discount if you wait for a bid to be announced. The time to build a thesis on these names is before the acquirer files a Rule 2.7 announcement.

Third, think hard about the sovereign wealth co-investment signal. ADIA and Mubadala are among the most sophisticated institutional allocators on the planet. When they co-invest alongside a top-quartile PE sponsor at £1.0 billion and £0.5 billion respectively into a single deal, they are communicating something about where they see long-duration value. Testing, inspection, and certification generates non-discretionary revenue tied to regulatory compliance. That is precisely the kind of asset these funds want in a period of elevated macro uncertainty. I covered the sovereign wealth co-investment trend in depth earlier this year, and the Intertek deal confirms the thesis.

The EQT and Intertek story is not finished. Regulatory approvals will take months. The scheme of arrangement process under UK law requires shareholder votes and court approval. But the terms are set, the price is agreed, and the strategic logic is clear. Intertek at £60 cash per share is EQT's bet that the public market left a lot of money on the table. The four-round bidding history suggests EQT believed that from the first day they submitted £51.50. I think they were right.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.